DARWIN EU® - Multiple myeloma: patient characterisation, treatments, and survival in the period 2012–2024

Study type

• Study topic:
  Disease /health condition
• Study topic, other:
  Multiple myeloma
• Study type:
  Non-interventional study
• Scope of the study:
  Disease epidemiology
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

Population studied

• Short description of the study population:
  The study population will include all individuals with a first diagnosis of multiple myeloma identified in the database between 01/01/2012 and 31/12/2024. Participants with a diagnosis of cancer (any, excluding non-melanoma skin cancer) any time prior to the diagnosis of multiple myeloma will be excluded.
• Age groups:
  • In utero
  • Paediatric Population (< 18 years)

    • Neonate

      • Preterm newborn infants (0 – 27 days)
      • Term newborn infants (0 – 27 days)
    • Infants and toddlers (28 days – 23 months)
    • Children (2 to < 12 years)
    • Adolescents (12 to < 18 years)
  • Adult and elderly population (≥18 years)

    • Adults (18 to < 65 years)

      • Adults (18 to < 46 years)
      • Adults (46 to < 65 years)
    • Elderly (≥ 65 years)

      • Adults (65 to < 75 years)
      • Adults (75 to < 85 years)
      • Adults (85 years and over)

Study design details

• Study design:
  A cohort study will be conducted using routinely collected health data. The study will comprise of:; • A patient-level characterisation will be conducted to address objective 1,2,3,4 to characterise patients with multiple myeloma diagnosed in the period 2012–2024. ;
• Main study objective:
  1. To describe demographic and clinical characteristics of patients with multiple myeloma at the time of diagnosis.; 2. To describe multiple myeloma treatments (including combinations and regimen types, e.g. triplets, etc.).; 3. To describe sequences of treatments and treatment combinations for multiple myeloma.; 4. To estimate the overall survival of incident multiple myeloma patients during the study period (2012–2024).;